Compare BELFB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | ORKA |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 7.1B |
| IPO Year | 1994 | 1997 |
| Metric | BELFB | ORKA |
|---|---|---|
| Price | $243.79 | $92.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $174.25 | $92.50 |
| AVG Volume (30 Days) | 122.6K | ★ 743.3K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,611,000.00 | N/A |
| Revenue This Year | $9.74 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $129.94 | $14.67 |
| 52 Week High | $335.29 | $115.52 |
| Indicator | BELFB | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 39.60 |
| Support Level | $219.03 | $82.34 |
| Resistance Level | $248.61 | $95.02 |
| Average True Range (ATR) | 10.45 | 5.23 |
| MACD | -2.78 | -2.39 |
| Stochastic Oscillator | 12.84 | 18.18 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.